About Zoetis Inc. (ZTS)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
ZTS Key Statistics
| Current Price | $122.23 | Market Cap | $53.9 billion |
|---|---|---|---|
| Daily Change | -2.96% | Volume | 4.1M |
| 52-Week High | $177.00 | 52-Week Low | $115.25 |
| P/E Ratio (TTM) | 20.93 | Forward P/E | 16.13 |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
ZTS Price Performance
Zoetis Inc. stock has returned -2.96% over the past day, -5.80% over the past week, -2.71% over the past month, and -1.92% over the past three months. The stock trades between a 52-week low of $115.25 and a high of $177.00.
ZTS Financial Fundamentals
Zoetis Inc. reports a return on equity (ROE) of +65.99%, operating margin of +38.00%, profit margin of +2823.49%, and revenue growth of +3.00%. The debt-to-equity ratio is 2.79. Current ratio stands at 3.03.
ZTS Earnings
Zoetis Inc.'s next earnings report is expected on 2026-05-05 (61 days away). The company has a +1.00% earnings beat rate with an average surprise of +5.31%. Earnings consistency is rated as "high".
ZTS Ownership
Institutional investors hold approximately +1.01% of ZTS shares across 10 institutions. Insider ownership is +0.00%. Insider sentiment is "bearish".
ZTS Short Interest
ZTS has a short interest of +3.87% of float with a short ratio (days to cover) of 3.3.
ZTS AI Analysis Signal
iGotFomo's AI-powered signal engine rates ZTS as "HOLD" with LOW confidence (score: 31/100). 5 signals are bullish, 7 are bearish, and 1 are neutral.
Frequently Asked Questions About ZTS
- What is Zoetis Inc. (ZTS)?
- Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commer...
- What is the current ZTS stock price?
- As of the latest trading session, ZTS trades at $122.23 per share, with a daily change of -2.96%.
- What is ZTS's market capitalization?
- Zoetis Inc. has a market capitalization of $53.9 billion, making it a large-cap stock.
- When does ZTS report earnings?
- Zoetis Inc.'s next earnings report is expected on 2026-05-05. Historically, the company has beaten earnings estimates +1.00% of the time.
- What sector does ZTS belong to?
- Zoetis Inc. operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. View all Healthcare stocks.